USD
+$0.00
(+0.00%
)At Close (As of Dec 12, 2025)
$364.41M
Market Cap
-
P/E Ratio
-2.69
EPS
$61.07
52 Week High
$13.70
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$59M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $1.6M |
| Capital Expenditures | $156K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$156K |
| Cashflow From Financing | $172M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$58M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Tectonic Therapeutic, Inc. is a biopharmaceutical innovator headquartered in Watertown, Massachusetts, specializing in the discovery and development of antibody-based therapies that target G-protein-coupled receptors (GPCRs), integral to numerous disease pathways. The company is dedicated to addressing significant unmet medical needs by developing novel treatment options for patients who have not responded well to current therapies. With a robust research and development pipeline, Tectonic is strategically positioned to lead advancements in biologic drugs, aiming to make impactful contributions to the therapeutic landscape.